#glasdegib

Glasdegib (Mechanism of Action)

In this article, we will discuss Glasdegib (Mechanism of Action). So, let’s get started. Mechanism of ActionGlasdegib is an inhibitor of the Hedgehog pathway. Glasdegib binds to and inhibits Smoothened, a transmembrane protein involved in hedgehog signal transduction.In a murine xenotransplant model of human AML, glasdegib in combination with low-dose cytarabine, inhibited increases in tumor…

In this article, we will discuss Glasdegib (Dosage Overview). So, let’s get started. IndicationsGlasdegib is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.Limitation of Use: Glasdegib has not been studied…

FDA approves new treatment for patients with acute myeloid leukemia

FDA approves new treatment Daurismo (glasdegib) for patients with acute myeloid leukemia The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic…